ANIP — ANI Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.37bn
- $1.46bn
- $486.82m
- 97
- 38
- 94
- 90
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 6.09 | -22.5 | -42.6 | -47.9 | 18.8 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 18.6 | 19 | 15.5 | 23.6 | 27.3 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -14.6 | -12.6 | -0.084 | -51.3 | 24.9 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 45.6 | 15.3 | 3.32 | -31.2 | 119 |
Capital Expenditures | -6.63 | -6.13 | -2.56 | -8.88 | -8.87 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -20.9 | -62.2 | -103 | -6.86 | -9.64 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Intangibles | |||||
Cash from Investing Activities | -27.5 | -68.3 | -105 | -15.7 | -18.5 |
Financing Cash Flow Items | 0 | — | -19.4 | 0 | -12.5 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.25 | -1.44 | 195 | -5.13 | 67.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 19.3 | -54.5 | 92.4 | -52.1 | 168 |